Sanofi Reports CHMP Recommendation For Suliqua - Quick Facts

(RTTNews) - Sanofi (SNYNF, SNY) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of Suliqua. CHMP recommended the use of Suliqua in combination with metformin for the treatment of adults with type 2 diabetes mellitus. The European Commission is expected to make a final decision in the coming months.

Suliqua is the brand name in Europe for the once-daily titratable fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide.